MKMohamed Kanj

Mohamed Kanj

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mohamed Kanj has a total of 113 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Multimodality Imaging for Left Atrial Appendage Closure: Practical Guidance Across Preprocedural, Intraprocedural, and Postprocedural Phases

    by Issam Motairek, Bryan Abadie, Paul C. Cremer, Mohamed Kanj, Serge Harb, Rogerio Teixeira, Stefano Nistri, Marta Sitges, Tyler Taigen, Heidi Ferrini, et al.

    Left atrial appendage closure is an increasingly used stroke prevention therapy for patients with atrial fibrillation who are unable to maintain long-term anticoagulation. Imaging quality and consistency are central to procedural safety and long-term outcomes, yet practice varies widely across centers. This review presents a practical, phase-based multimodality imaging framework intended to provide guidance and minimum standards for image acquisition and interpretation across all phases of left atrial appendage closure care, including preprocedural planning and thrombus exclusion, intraprocedural guidance and complication detection, and postprocedural surveillance for device-related thrombus and peridevice leak. Because sizing rules, sealing mechanisms, and leak patterns differ between the 2 contemporary platforms, device-specific considerations for the Watchman and Amulet systems are addressed throughout. Transesophageal echocardiography remains the reference standard for thrombus detection and procedural guidance, while cardiac computed tomography offers high spatial resolution, detailed 3-dimensional characterization, and complementary leak assessment, with optimal modality selection influenced by patient characteristics, operator expertise, and institutional resources. Intracardiac echocardiography and mini transesophageal echocardiographic support anesthesia-sparing workflows. Standardized device-related thrombus and peridevice leak classification and harmonized imaging protocols can enhance reproducibility and facilitate cross-center comparisons. Emerging technologies including computed tomography first workflows, 4-dimensional imaging, AI applications, and computational modeling further advance precision planning and surveillance.

  • Open Access

    Impact of prophylactic protamine administration following atrial fibrillation ablation on vascular and pericardial complications

    by Tess Calcagno, V Karthik, Bryan Baranowski, Mandeep Bhargava, Thomas Callahan, Mina K Chung, Roy Chung, Koji Higuchi, Ayman Hussein, Mohamed Kanj, et al.

  • Open Access

    Anatomical Approach from the Coronary Sinus of Valsalva for Para-Hisian Premature Ventricular Contractions: Safety and Outcomes

    by Masafumi Sugawara, Jakub Sroubek, Justin Lee, Bryan Baranowski, Mandeep Bhargava, Thomas Callahan, Mina Chung, Thomas Dresing, Ayman Hussein, Mohamed Kanj, et al.

    Background: While various reports described the characteristics and catheter ablation strategies for para-Hisian premature ventricular contraction (PVC), the patient population were limited in previous literatures and optimal approach remain unknown. This study sought to comprehensively assess the safety and outcomes of catheter ablation for para-Hisian PVC, with a particular focus on the safety and efficacy of ablation from aortic coronary cusps. Methods: A total of 122 para-Hisian PVC cases were retrospectively included in this study. The acute and clinical outcomes of ablation, especially the success rate, the rate of conduction system injury, and the ablation site (right side, left side His bundle (HB) region, and aortic coronary cusp), were analyzed. Results: Acute procedural success was achieved in 89 patients (73%). However, long-term clinical success (≥80% reduction of PVC burden) was achieved only in 52% of acute-success cases. Cusp ablation was attempted in 35 patients (31%). Cusp ablation was performed significantly more often in clinical-success cases than clinical-failed cases (38% vs.7% P = 0.005), although ablation from multiple locations was still required. In 28 of 35 cases (80%) who underwent cusp ablation, cusp ablation affected PVC by eliminating, transiently suppressing, or changing morphology. Predictors of successful cusp ablation included earlier activation at the cusp and close anatomical proximity to the earliest site at the HB region. Conduction system injury occurred in 31 cases of the entire cohort, mainly during the HB-region ablation, with only one event during cusp ablation. Conclusion: In this large cohort of para-Hisian PVC ablation, an anatomical approach from the adjacent coronary cusp ablation can be considered as an effective and safe strategy. Early local activation and a close anatomical proximity between the earliest para-Hisian site and the coronary cusp region are predictors of ablation success with this approach. What is known: Catheter ablation of para-Hisian premature ventricular contraction (PVC) is challenging due to the proximity to the His bundle (HB) and/or potentially intramural sources. Catheter mapping and ablation from multiple sites, including aortic coronary cusps, have been reported as potential alternative approaches, however systematic analyses of the ablation outcome and safety for para-Hisian PVC remain scarce. What the study adds: Clinical-success rate of radiofrequency (RF) ablation for para-Hisian PVC was still suboptimal (52%). However, the cases undergoing cusp ablation were associated with a better success rate (85%) than those with direct ablation to the HB region alone (42%), indicating this approach may improve the outcome. The anatomical features, including PVC earliest activation site above the HB or within short distance from the coronary cusp, may predict successful PVC elimination from the coronary cusp. Conduction system injury, including minor forms, occurred in approximately 30% cases during the RF ablation near the HB region, while only one AH prolongation observed during cusp ablation, indicating superior safety of cusp ablation.

  • Factors Influencing Lesion Titration in a Monopolar Pulsed-Field Ablation Point Catheter: A Preclinical Study

    by Arwa Younis, Joe Demian, Savannah Bifulco, Lauren Lehn, Ioan Liuba, Samuel Hinds, Pasquale Santangeli, Ayman A. Hussein, Mohamad Mdaihly, Tyler L. Taigen, et al.

    BACKGROUND: Despite the rise of pulsed-field ablation (PFA), predicting and titrating lesion geometry remains challenging. This study aimed to find modifiable parameters that can accurately and repeatedly predict focal PFA lesions across a range of dimensions and to develop a model to predict lesion geometry. METHODS: An in vivo study was performed in 9 swine using an investigational dual-energy contact-force focal catheter with local impedance. Ablations were performed endocardially in the right and left ventricles using settings specifically selected to provide a wide range of lesion dimensions. Predefined PFA applications (1, 2, or 4) were delivered while maintaining different contact-force values (5–45 g). Four different voltages were used (1.0, 1.4, 2.0, and 2.2 kV). Following a 1-week survival period, the animals were euthanized for histopathologic examination. RESULTS: In the study characterization data set, a total of 78 PFA lesions were analyzed. Lesion depth ranged from 1.4 mm to 12.3 mm, while lesion width ranged from 3.3 mm to 21.2 mm. All 3 tested parameters—contact force, number of applications, and voltage—demonstrated a positive linear correlation with lesion depth ( P R =0.83; P R =0.76; P <0.0001). A perpendicular catheter orientation was correlated with deeper lesions than a parallel orientation. No ST-segment elevations or sustained ventricular arrhythmias were observed. CONCLUSIONS: Our findings demonstrate that PFA can be effectively titrated and predicted using the Focal FARAPULSE Index Model to create lesions of varying depths (1–12 mm), with these results being specific to the proprietary waveform and catheter used.


  • Open Access

    Intracardiac echocardiography guided anatomical approach to cardioneuroablation: feasibility and outcomes

    by Medhat Farwati, Ayman A Hussein, Santiago Giraldo, William Bautista, Koji Higuchi, Bryan Baranowski, Mandeep Bhargava, Thomas D Callahan, Mina K Chung, Roy Chung, et al.

    Aims: Anatomical studies have documented a close topographical relationship between the ganglionated plexi (GP) containing parasympathetic inputs to the sinus node (SN) and atrioventricular node (AVN) and the epicardial fat pads (FPs) within the Waterston’s interatrial groove. We aimed to investigate the feasibility and outcomes of a novel anatomical approach to cardioneuroablation (CNA) that targets the atrial areas adjacent to the interatrial FPs identified with intracardiac echocardiography (ICE). Methods and results: About 17 patients [37.3 ± 10.2 years, 47% female] undergoing CNA for recurrent vasovagal syncope and documented sinus pauses (n = 13, 76%) and/or AVN block (AVB, n = 4, 16%) were included. The right superior RS-FP containing the RS-GP (target for SN vagal denervation) and the right inferior RI-FP containing the RI-GP (target for AVN vagal denervation) were identified with ICE and reconstructed on a 3D electroanatomic map. At baseline, all patients had provocable sinus pauses/AVB with extracardiac high-frequency vagal stimulation (ECVS). The target FPs could be identified in all patients and were adjacent to septal LA and RA sites covering an average surface area of 3.7 ± 1.4 cm2 and 2.97 ± 1.21 cm2, respectively. A total of 33 ± 15 RF ablations (30–40W, 60 s) were delivered to cover the target LA/RA area. A > 25% shortening of the PP interval was observed within the first 1–2 RF lesions in all cases. After ablation, complete abolition of sinus pauses/AVB response with ECVS was achieved in all patients, and 2 mg of atropine infusion resulted in no PP/PR interval change. After a median follow-up of 12 months (range 4–25 months), 16 patients (94%) remained free of recurrent symptoms (1 patient underwent repeat CNA for recurrent pre-syncope and AVB, 1 patient underwent PPM implant following ECG recording of asymptomatic diurnal AVB). Conclusion: An ICE-guided anatomical approach to CNA targeting visible FPs at the Waterston’s groove is a feasible and effective strategy to achieve SN/AVN vagal denervation, with good outcomes at mid-term follow-up.


  • Prevalence and Clinical Course of Suspected Acute Pericarditis Following Atrial Pulsed-Field Ablation

    by Aleksandar Izda, Anika Sonig, Alyson Brown, Erin Capodanno, Maria Matteo, Bryan Baranowski, Mandeep Bhargava, Thomas D. Callahan, Thomas J. Dresing, Koji Higuchi, et al.


  • Open Access

    Pharmacologic parasympathetic withdrawal to facilitate activation mapping and ablation of infrequent intraprocedural premature ventricular contractions

    by Andrew Abboud, Jeffrey Hedley, Nolan Hight, Jakub Sroubek, Justin Lee, Koji Higuchi, Arwa Younis, Hiroshi Nakagawa, Mandeep Bhargava, Ayman Hussein, et al.


  • Open Access

    Acute post-procedural inducibility is a poor predictor of clinical outcomes in high-risk patients (PAINESD > 17) undergoing scar-related ventricular tachycardia ablation

    by Joseph Sipko, Bryan Baranowski, Mandeep Bhargava, Thomas D Callahan, Thomas J Dresing, Koji Higuchi, Ayman A Hussein, Mohamed Kanj, Justin Lee, David O Martin, et al.

    Ventricular tachycardia (VT) non-inducibility in response to programmed ventricular stimulation (PVS) is a widely used procedural endpoint for VT ablation despite inconclusive evidence with respect to clinical outcomes in high-risk patients. The aim is to determine the utility of acute post-ablation VT inducibility as a predictor of VT recurrence, mortality, or mortality equivalent in high-risk patients. We conducted a retrospective analysis of high-risk patients (defined as PAINESD > 17) who underwent scar-related VT ablation at our institution between July 2010 and July 2022. Patients’ response to PVS (post-procedure) was categorized into three groups: Group A, no clinical VT or VT with cycle length > 240 ms inducible; Group B, only non-clinical VT with cycle length > 240 ms induced; and Group C, all other outcomes (including cases where no PVS was performed). The combined primary endpoint included death, durable left ventricular assist device placement, and cardiac transplant (Cox analysis). Ventricular tachycardia recurrence was considered a secondary endpoint (competing risk analysis). Of the 1677 VT ablation cases, 123 cases met the inclusion criteria for analysis. During a 19-month median follow-up time (interquartile range 4–43 months), 82 (66.7%) patients experienced the composite primary endpoint. There was no difference between Groups A and C with respect to the primary [hazard ratio (HR) = 1.21 (0.94–1.57), P = 0.145] or secondary [HR = 1.18 (0.91–1.54), P = 0.210] outcomes. These findings persisted after multivariate adjustments. The size of Group B (n = 13) did not permit meaningful statistical analysis. The results of post-ablation PVS do not significantly correlate with long-term outcomes in high-risk (PAINESD > 17) VT ablation patients.


  • Impact of redo ablation for atrial fibrillation on patient‐reported outcomes and quality of life

    by Medhat Farwati, Mustapha Amin, Walid I. Saliba, Hiroshi Nakagawa, Khaldoun G. Tarakji, Mohamed Diab, Anna Scandinaro, Ruth Madden, Patricia Bouscher, Shunsuke Kuroda, et al.

    Introduction: Catheter ablation for atrial fibrillation (AF) is frequently used for the purpose of rhythm control and improved quality of life (QoL). Although success rates are high, a significant proportion of patients require redo ablation. Data are scarce on patient‐centered outcomes and QoL in patients undergoing redo AF ablation. We aimed to assess QoL and clinical outcomes using a large prospectively maintained patient‐reported outcomes (PRO) registry.Methods: All patients undergoing redo AF ablation (2013–2016) at our center were enrolled in a prospective registry for outcomes and assessed for QoL using automated PRO surveys (baseline, 3 and 6 months after ablation, every 6 months thereafter). Data were collected over 3 years of follow‐up. The atrial fibrillation symptom severity scale (AFSSS) was used as the main measure for QoL. Additional variables included patient‐reported improvement, AF burden, and AF‐related healthcare utilization including emergency room (ER) visits and hospitalizations.Results: A total of 848 patients were included (28% females, mean age 63.8, 51% persistent AF). By automated PRO, significant improvement in QoL was noted (baseline median AFSSS of 12 [5–18] and ranged between 2 and 4 on subsequent assessments; p < .0001), with ≥70%of patients reported remarkable improvement in their AF‐related symptoms. The proportion of patients in AF at the time of baseline survey was 36%, and this decreased to p < .0001). AF burden was significantly reduced (including frequency and duration of episodes; p < .0001), with an associated decrease in healthcare utilization after 6 months from the time of ablation (including ER visits and hospitalizations; p < .0001). The proportion of patients on anticoagulants or antiarrhythmics decreased on follow‐up across all time points (p < .0001 for all variables).Conclusion: Most patients derive significant QoL benefit from redo AF ablation; with reduction of both AF burden and healthcare utilization.


  • Open Access

    Better prediction of stroke in atrial fibrillation with incorporation of cancer in CHA2DS2VASC score: CCHA2DS2VASC score

    by Brandon Bungo, Pulkit Chaudhury, Michael Arustamyan, Rishi Rikhi, Muzna Hussain, Patrick Collier, Mohamed Kanj, Alok A. Khorana, Amgad Mentias, Rohit Moudgil